Crescent Biopharma Stock (NASDAQ:CBIO)


ForecastOwnershipFinancialsChart

Previous Close

$12.27

52W Range

$10.83 - $63.00

50D Avg

$12.87

200D Avg

$20.02

Market Cap

$157.68M

Avg Vol (3M)

$114.78K

Beta

-

Div Yield

-

CBIO Company Profile


Crescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

33

IPO Date

Jan 10, 2014

Website

CBIO Performance


CBIO Financial Summary


Dec 24
Revenue-
Operating Income$-68.76K
Net Income$-71.47K
EBITDA-
Basic EPS$-13.45
Diluted EPS$-13.45

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts


Q1 24May 06, 24 | 12:00 AM
Q4 23Mar 27, 24 | 8:30 AM
Q3 23Nov 03, 23 | 8:30 AM

Peer Comparison


TickerCompany
SLNSilence Therapeutics plc
CDTXCidara Therapeutics, Inc.
CTMXCytomX Therapeutics, Inc.
MGNXMacroGenics, Inc.
GLMDGalmed Pharmaceuticals Ltd.
APLTApplied Therapeutics, Inc.